- Home
- STTK vs NCTY Comparison
STTK vs NCTY Comparison
Compare STTK & NCTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STTK | NCTY |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 97.7M |
| IPO Year | 2020 | 2004 |
Fundamental Metrics
Financial Performance| Metric | STTK | NCTY |
|---|---|---|
| Price | $4.76 | $7.04 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 626.6K | 35.6K |
| Earning Date | 11-06-2025 | 03-27-2015 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,000,000.00 | ★ $11,403,864.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $5.95 |
| 52 Week High | $4.89 | $17.83 |
Technical Indicators
Market Signals| Indicator | STTK | NCTY |
|---|---|---|
| Relative Strength Index (RSI) | 75.73 | 48.38 |
| Support Level | $4.09 | $6.47 |
| Resistance Level | $4.89 | $7.16 |
| Average True Range (ATR) | 0.34 | 0.52 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 89.50 | 60.45 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.